472 related articles for article (PubMed ID: 30042946)
1. The Role of Eosinophils in Bullous Pemphigoid: A Developing Model of Eosinophil Pathogenicity in Mucocutaneous Disease.
Amber KT; Valdebran M; Kridin K; Grando SA
Front Med (Lausanne); 2018; 5():201. PubMed ID: 30042946
[TBL] [Abstract][Full Text] [Related]
2. Eosinophils in bullous pemphigoid.
Jones VA; Patel PM; Amber KT
Panminerva Med; 2021 Sep; 63(3):368-378. PubMed ID: 32536149
[TBL] [Abstract][Full Text] [Related]
3. Eosinophil localization to the basement membrane zone is autoantibody- and complement-dependent in a human cryosection model of bullous pemphigoid.
Messingham KN; Wang JW; Holahan HM; Srikantha R; Aust SC; Fairley JA
Exp Dermatol; 2016 Jan; 25(1):50-5. PubMed ID: 26475989
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a role of eosinophils in blister formation in bullous pemphigoid.
de Graauw E; Sitaru C; Horn M; Borradori L; Yousefi S; Simon HU; Simon D
Allergy; 2017 Jul; 72(7):1105-1113. PubMed ID: 28135772
[TBL] [Abstract][Full Text] [Related]
5. Human eosinophils express the high affinity IgE receptor, FcεRI, in bullous pemphigoid.
Messingham KN; Holahan HM; Frydman AS; Fullenkamp C; Srikantha R; Fairley JA
PLoS One; 2014; 9(9):e107725. PubMed ID: 25255430
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
Ishiura N; Fujimoto M; Watanabe R; Nakashima H; Kuwano Y; Yazawa N; Echigo T; Okochi H; Tamaki K
J Dermatol Sci; 2008 Feb; 49(2):153-61. PubMed ID: 17920818
[TBL] [Abstract][Full Text] [Related]
7. Eosinophils Mediate Tissue Injury in the Autoimmune Skin Disease Bullous Pemphigoid.
Lin L; Hwang BJ; Culton DA; Li N; Burette S; Koller BH; Messingham KA; Fairley JA; Lee JJ; Hall RP; An L; Diaz LA; Liu Z
J Invest Dermatol; 2018 May; 138(5):1032-1043. PubMed ID: 29246800
[TBL] [Abstract][Full Text] [Related]
8. Eosinophils as putative therapeutic targets in bullous pemphigoid.
Simon D; Borradori L; Simon HU
Exp Dermatol; 2017 Dec; 26(12):1187-1192. PubMed ID: 28833620
[TBL] [Abstract][Full Text] [Related]
9. Bullous pemphigoid: interaction of interleukin 5, anti-basement membrane zone antibodies and eosinophils. A preliminary observation.
Engineer L; Bhol K; Kumari S; Razzaque Ahmed A
Cytokine; 2001 Jan; 13(1):32-38. PubMed ID: 11145840
[TBL] [Abstract][Full Text] [Related]
10. Immunopathology of bullous pemphigoid, an autoimmune and inflammatory skin blistering disease.
Liu Z
Keio J Med; 2003 Jun; 52(2):128-33. PubMed ID: 12862365
[TBL] [Abstract][Full Text] [Related]
11. Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid.
Chen F; Wang Y; Chen X; Yang N; Li L
Ann Med; 2023 Dec; 55(1):1156-1170. PubMed ID: 36999962
[No Abstract] [Full Text] [Related]
12. Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles.
Tanaka M; Hashimoto T; Dykes PJ; Nishikawa T
Clin Exp Dermatol; 1996 Jan; 21(1):23-7. PubMed ID: 8689764
[TBL] [Abstract][Full Text] [Related]
13. Eosinophils, Basophils, and Neutrophils in Bullous Pemphigoid.
Limberg MM; Weihrauch T; Gray N; Ernst N; Hartmann K; Raap U
Biomolecules; 2023 Jun; 13(7):. PubMed ID: 37509055
[TBL] [Abstract][Full Text] [Related]
14. Eosinophil-derived galectin-10 upregulates matrix metalloproteinase expression in bullous pemphigoid blisters.
Sato T; Chiba T; Nakahara T; Watanabe K; Sakai S; Noguchi N; Noto M; Ueki S; Kono M
J Dermatol Sci; 2023 Oct; 112(1):6-14. PubMed ID: 37640566
[TBL] [Abstract][Full Text] [Related]
15. High Index Values of Enzyme-Linked Immunosorbent Assay for BP180 at Baseline Predict Relapse in Patients With Bullous Pemphigoid.
Koga H; Teye K; Ishii N; Ohata C; Nakama T
Front Med (Lausanne); 2018; 5():139. PubMed ID: 29868591
[TBL] [Abstract][Full Text] [Related]
16. IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants.
Freire PC; Muñoz CH; Stingl G
Br J Dermatol; 2017 Dec; 177(6):1644-1653. PubMed ID: 28868796
[TBL] [Abstract][Full Text] [Related]
17. Bullous pemphigoid-What do we know about the most recent therapies?
Zeng FAP; Murrell DF
Front Med (Lausanne); 2022; 9():1057096. PubMed ID: 36405625
[TBL] [Abstract][Full Text] [Related]
18. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
Chijiwa C; Takeoka S; Kamata M; Tateishi M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Watanabe S; Tada Y
J Dermatol; 2018 May; 45(5):596-599. PubMed ID: 29411416
[TBL] [Abstract][Full Text] [Related]
19. Insights Into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms.
Cole C; Vinay K; Borradori L; Amber KT
Front Immunol; 2022; 13():912876. PubMed ID: 35874745
[TBL] [Abstract][Full Text] [Related]
20. The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid.
Messingham KN; Crowe TP; Fairley JA
Front Immunol; 2019; 10():2331. PubMed ID: 31636640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
